Illumina Granted Registration in Russia for Clinical NGS Platform, Reagents
March 5, 2021
Illumina s NextSeq™ 550Dx next-generation sequencing (NGS) platform (pictured), associated reagent kits, and reagents for the company’s MiSeq™Dx have all been approved for use in Russia by the country’s medical device regulatory agency, Roszdravnadzor. [Illumina]
Illumina said that its NextSeq 550Dx next-generation sequencing (NGS) platform, associated reagent kits, and reagents for the company’s MiSeq Dx have all been approved for use in Russia by the country’s medical device regulatory agency, Roszdravnadzor.
Roszdravnadzor has granted medical device registration to NextSeq 550Dx, which Illumina launched in 2017 as its second FDA-regulated and CE-IVD marked clinical NGS system, with the goal of extending NGS to clinical labs.